Cargando…
Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature
Colorectal cancer is one of the most frequent forms of cancer both in men and women, and patients with metastatic disease are now being exposed to an increasing number of therapeutic agents to improve the survival outcomes. Vascular endothelial growth factor (VEGF) has o key role in the tumor growth...
Autores principales: | HOPIRTEAN, CLAUDIU, NAGY, VIORICA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iuliu Hatieganu University of Medicine and Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808259/ https://www.ncbi.nlm.nih.gov/pubmed/29440946 http://dx.doi.org/10.15386/cjmed-881 |
Ejemplares similares
-
The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013) -
Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
por: Schiffmann, Lars Mortimer, et al.
Publicado: (2018) -
Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review
por: Li, Yong, et al.
Publicado: (2021) -
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
por: Chen, Datian, et al.
Publicado: (2019) -
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013)